alphaPlGF: a new kid on the antiangiogenesis block.
An agent that blocks tumor angiogenesis, growth, and metastasis without affecting normal tissues -- whether used alone or in combination with currently approved drugs -- would change the way we treat cancer. In this issue, Fischer et al. (2007) offer compelling evidence that a monoclonal antibody against placental growth factor (PlGF), a member of the VEGF family, has such potential in mice.
Jain
Rakesh K
RK
Steele Lab of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. jain@steele.mgh.harvard.edu
Xu
Lei
L
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D051379:Mice; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D000072483:Placenta Growth Factor; D011257:Pregnancy Proteins / Q000037:antagonists & inhibitors*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C000608036:PGF protein, human; C000608037:Pgf protein, mouse; D011257:Pregnancy Proteins; D000072483:Placenta Growth Factor; D040301:Vascular Endothelial Growth Factor Receptor-2